Aldose reductase inhibitors and diabetic kidney disease

Current Opinion in Investigational Drugs

Volumn 11, Issue 4, 2010, Pages 402-416

  Oates, Peter J ^a  

^a Oates Biomedical Consulting LLC   (United States)

Author keywords

AKR1B1 gene; Aldose reductase inhibitor; Diabetic kidney disease; Diabetic nephropathy; Hemodynamics; Oxidative stress; Polyol pathway; Renal fibrosis

Indexed keywords

ALDEHYDE REDUCTASE; ALDOSE REDUCTASE INHIBITOR; ARI 809; EPALRESTAT; FIDARESTAT; IMIRESTAT; INSULIN; PLACEBO; POLYOL; RANIRESTAT; SORBINIL; UNCLASSIFIED DRUG; ZOPOLRESTAT;

ANTIALBUMINURIC EFFECT; ANTIFIBROTIC EFFECT; CLINICAL TRIAL; DIABETIC NEPHROPATHY; DISEASE COURSE; DRUG MECHANISM; DRUG STRUCTURE; ENZYME LOCALIZATION; GENETIC ASSOCIATION; HEMODYNAMICS; HISTOPATHOLOGY; HUMAN; KIDNEY HYPERTROPHY; KIDNEY TUBULE; METABOLISM; NEUROPATHY; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; REVIEW;

ALDEHYDE REDUCTASE; ANIMALS; DIABETES MELLITUS; DIABETIC NEPHROPATHIES; ENZYME INHIBITORS; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY; RATS;

EID: 77950168857     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (168)

1. Parving HH, Mauer M, Ritz E: Diabetic nephropathy. In: Brenner and Rector's The Kidney, 2. Brenner BM (Ed), Saunders Elsevier, Philadelphia, PA, USA (2008):1265-1298.
2. Centers for Disease Control and Prevention: National Diabetes Fact Sheet: General Information and National Estimates on Diabetes in the United States, 2007. US Department of Health and Human Services, Atlanta, GA, USA (2008).
3. The Diabetes Atlas: International Diabetes Federation, Brussels, Belgium (2009). www.diabetesatlas.org/content/diabetesand- impaired-glucose-tolerance
4. Fioretto P, Caramori ML, Mauer M: The kidney in diabetes: Dynamic pathways of injury and repair. The Camillo Golgi Lecture 2007. Diabetologia (2008) 51(8):1347-1355.
5. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group, Nathan DM, Zinman B, Cleary PA, Backlund JY, Genuth S, Miller R, Orchard TJ: Modern-day clinical course of type 1 diabetes mellitus after 30 years' duration: The diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983-2005). Arch Intern Med (2009) 169(14):1307-1316.
6. USRDS 2009 Annual data report: National Institute of Diabetes and Digestive and Kidney Diseases, NIH, Bethesda, MD, USA (2009). www.usrds.org/adr.htm
7. Ficociello LH, Perkins BA, Silva KH, Finkelstein DM, Ignatowska- Switalska H, Gaciong Z, Cupples LA, Aschengrau A, Warram JH, Krolewski AS: Determinants of progression from microalbuminuria to proteinuria in patients who have type 1 diabetes and are treated with angiotensin-converting enzyme inhibitors. Clin J Am Soc Nephrol (2007) 2(3):461-469.
8. Bruno S, Cattaneo D, Perico N, Remuzzi G: Emerging drugs for diabetic nephropathy. Expert Opin Emerg Drugs (2005) 10(4): 747-771.
9. Oates PJ: Aldose reductase, still a compelling target for diabetic neuropathy. Curr Drug Targets (2008) 9(1):14-36.
10. Lorenzi M, Oates PJ: The polyol pathway and diabetic retinopathy In: Diabetic retinopathy. Duh E (Ed), Humana Press, Totowa, NJ, USA (2008):159-186.
11. Stribling D, Armstrong FM, Harrison HE: Aldose reductase in the etiology of diabetic complications: 2. Nephropathy. J Diabetic Complications (1989) 3(2):70-76.
12. Sarges R, Oates PJ: Aldose reductase inhibitors: Recent developments. Prog Drug Res (1993) 40:99-161.
13. Oates PJ: Diabetic nephropathy, renal hemodynamics, and aldose reductase inhibitors. Drug Dev Res (1994) 32(2):104-116.
14. Dunlop M: Aldose reductase and the role of the polyol pathway in diabetic nephropathy. Kidney Int (2000) 58(Suppl 77):S3-S12.
15. Mogensen CE: Early glomerular hyperfiltration in insulindependent diabetics and late nephropathy. Scand J Clin Lab Invest (1986) 46(3):201-206.
16. Amin R, Turner C, van Aken S, Bahu TK, Watts A, Lindsell DR, Dalton RN, Dunger DB: The relationship between microalbuminuria and glomerular filtration rate in young type 1 diabetic subjects: The Oxford Regional Prospective Study. Kidney Int (2005) 68(4):1740-1749.
17. Deen WM, Robertson CR, Brenner BM: A model of glomerular ultrafiltration in the rat. Am J Physiol (1972) 223(5):1178-1183.
18. Hostetter TH, Troy JL, Brenner BM: Glomerular hemodynamics in experimental diabetes mellitus. Kidney Int (1981) 19(3): 410-415.
19. Mogensen CE: Prediction of clinical diabetic nephropathy in IDDM patients. Alternatives to microalbuminuria? Diabetes (1990) 39(7):761-767.
20. USRDS Coordinating Center: U.S. Renal Data System, USRDS 2008 Annual Data Report: Atlas of Chronic Kidney Disease and End-stage Renal Disease in the United States. NIH, Bethesda, MD, USA (2008).
21. Macisaac RJ, Tsalamandris C, Thomas MC, Premaratne E, Panagiotopoulos S, Smith TJ, Poon A, Jenkins MA, Ratnaike SI, Power DA, Jerums G: The accuracy of cystatin C and commonly used creatinine-based methods for detecting moderate and mild chronic kidney disease in diabetes. Diabet Med (2007) 24(4):443-448.
22. Perkins BA, Krolewski AS: Early nephropathy in type 1 diabetes: The importance of early renal function decline. Curr Opin Nephrol Hypertens (2009) 18(3):233-240.
23. Wolkow PP, Niewczas MA, Perkins B, Ficociello LH, Lipinski B, Warram JH, Krolewski AS: Association of urinary inflammatory markers and renal decline in microalbuminuric type 1 diabetics. J Am Soc Nephrol (2008) 19(4):789-797.
24. Perkins BA, Ficociello LH, Silva KH, Finkelstein DM, Warram JH, Krolewski AS: Regression of microalbuminuria in type 1 diabetes. N Engl J Med (2003) 348(23):2285-2293.
25. Steinke JM, Sinaiko AR, Kramer MS, Suissa S, Chavers BM, Mauer M, International Diabetic Nephopathy Study Group: The early natural history of nephropathy in type 1 diabetes: III. Predictors of 5-year urinary albumin excretion rate patterns in initially normoalbuminuric patients. Diabetes (2005) 54(7):2164-2171.
26. Thomas MC, Macisaac RJ, Jerums G, Weekes A, Moran J, Shaw JE, Atkins RC: Nonalbuminuric renal impairment in type 2 diabetic patients and in the general population (National Evaluation of the Frequency of Renal Impairment Co-existing with NIDDM [NEFRON] 11). Diabetes Care (2009) 32(8):1497-1502.
27. Retnakaran R, Cull CA, Thorne KI, Adler AI, Holman RR, UKPDS Study Group: Risk factors for renal dysfunction in type 2 diabetes: UK Prospective Diabetes Study 74. Diabetes (2006) 55(6):1832-1839.
28. Steffes MW, Osterby R, Chavers B, Mauer SM: Mesangial expansion as a central mechanism for loss of kidney function in diabetic patients. Diabetes (1989) 38(9):1077-1081.
29. Fogo AB, Kashgarian M: Vascular diseases. In: Diagnostic Atlas of Renal Pathology. Elsevier Ltd, Philadelphia, PA, USA (2005):277-288.
30. Gilbert RE, Cooper ME: The tubulointerstitium in progressive diabetic kidney disease: More than an aftermath of glomerular injury? Kidney Int (1999) 56(5):1627-1637.
31. Cooper ME: Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy. Diabetologia (2001) 44(11):1957-1972.
32. Raptis AE, Viberti G: Pathogenesis of diabetic nephropathy. Exp Clin Endocrinol Diabetes (2001) 109(Suppl 2):S424-S437.
33. No authors listed: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med (1993) 329(14):977-986.
34. Taal MW, Brenner BM: Renoprotective benefits of RAS inhibition: From ACEI to angiotensin II antagonists. Kidney Int (2000) 57(5):1803-1817.
35. Brenner BM, Lawler EV, Mackenzie HS: The hyperfiltration theory: A paradigm shift in nephrology. Kidney Int (1996) 49(6):1774-1777.
36. Candido R, Burrell LM, Jandeleit-Dahm KAM, Cooper ME: Vasoactive peptides and the kidney. In: Brenner & Rector's The Kidney. Brenner BM (Ed), Saunders Elsevier, Philadelphia, PA, USA (2008):333-362.
37. Zhuo JL, Li XC: Novel roles of intracrine angiotensin II and signalling mechanisms in kidney cells. J Renin Angiotensin Aldosterone Syst (2007) 8(1):23-33.
38. Hayward LD, Angyal SJ: A symmetry rule for the circular dichroism of reducing sugars, and the proportion of carbonyl forms in aqueous solutions thereof. Carbohydr Res (1977) 53(1):13-20.
39. Cohen MP, Ziyadeh FN, Hong SW, Shearman CW, Hud E, Lautenslager GT, Iglesias-de La Cruz MC, Chen S: Inhibiting albumin glycation in vivo ameliorates glomerular overexpression of TGF-1. Kidney Int (2002) 61(6):2025-2032.
40. Ahmed N, Thornalley PJ: Advanced glycation endproducts: What is their relevance to diabetic complications? Diabetes Obes Metab (2007) 9(3):233-245.
41. Baynes JW, Thorpe SR: Role of oxidative stress in diabetic complications: A new perspective on an old paradigm. Diabetes (1999) 48(1):1-9.
42. Brownlee M, Cerami A, Vlassara H: Advanced products of nonenzymatic glycosylation and the pathogenesis of diabetic vascular disease. Diabetes Metab Rev (1988) 4(5):437-451.
43. Yan SF, Barile GR, D'Agati V, Du Yan S, Ramasamy R, Schmidt AM: The biology of RAGE and its ligands: Uncovering mechanisms at the heart of diabetes and its complications. Curr Diab Rep (2007) 7(2):146-153.
44. Coughlan MT, Thorburn DR, Penfold SA, Laskowski A, Harcourt BE, Sourris KC, Tan AL, Fukami K, Thallas-Bonke V, Nawroth PP, Brownlee M et al: RAGE-induced cytosolic ROS promote mitochondrial superoxide generation in diabetes. J Am Soc Nephrol (2009) 20(4):742-752.
45. Wendt TM, Tanji N, Guo J, Kislinger TR, Qu W, Lu Y, Bucciarelli LG, Rong LL, Moser B, Markowitz GS, Stein G et al: RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol (2003) 162(4):1123-1137.
46. Ido Y, Chang KC, Lejeune WS, Bjercke RJ, Reiser KM, Williamson JR, Tilton RG: Vascular dysfunction induced by AGE is mediated by VEGF via mechanisms involving reactive oxygen species, guanylate cyclase, and protein kinase C. Microcirculation (2001) 8(4):251-263.
47. Heilig CW, Brosius FC 3rd, Cunningham C: Role for GLUT1 in diabetic glomerulosclerosis. Expert Rev Mol Med (2006) 8(4):1-18.
48. Beyer-Mears A, Ku L, Cohen MP: Glomerular polyol accumulation in diabetes and its prevention by oral sorbinil. Diabetes (1984) 33(6):604-607.
49. Kikkawa R, Umemura K, Haneda M, Arimura T, Ebata K, Shigeta Y: Evidence for existence of polyol pathway in cultured rat mesangial cells. Diabetes (1987) 36(2):240-243.
50. Noh H, King GL: The role of protein kinase C activation in diabetic nephropathy. Kidney Int Suppl (2007) (106):S49-S53.
51. Singh LP, Cheng DW, Kowluru R, Levi E, Jiang Y: Hexosamine induction of oxidative stress, hypertrophy and laminin expression in renal mesangial cells: Effect of the anti-oxidant α-lipoic acid. Cell Biochem Funct (2007) 25(5):537-550.
52. Brown DI, Griendling KK: Nox proteins in signal transduction. Free Radic Biol Med (2009) 47(9):1239-1253.
53. Tojo A, Asaba K, Onozato ML: Suppressing renal NADPH oxidase to treat diabetic nephropathy. Expert Opin Ther Targets (2007) 11(8):1011-1018.
54. Maia L, Duarte RO, Ponces-Freire A, Moura JJ, Mira L: NADH oxidase activity of rat and human liver xanthine oxidoreductase: Potential role in superoxide production. J Biol Inorg Chem (2007) 12(6):777-787.
55. Siu YP, Leung KT, Tong MK, Kwan TH: Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis (2006) 47(1):51-59.
56. Rosca MG, Mustata TG, Kinter MT, Ozdemir AM, Kern TS, Szweda LI, Brownlee M, Monnier VM, Weiss MF: Glycation of mitochondrial proteins from diabetic rat kidney is associated with excess superoxide formation. Am J Physiol (2005) 289(2):F420-430.
57. Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, Yorek MA, Beebe D, Oates PJ, Hammes HP, Giardino I et al: Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature (2000) 404(6779):787-790.
58. Qian Y, Feldman E, Pennathur S, Kretzler M, Brosius FC 3rd: From fibrosis to sclerosis: Mechanisms of glomerulosclerosis in diabetic nephropathy. Diabetes (2008) 57(6):1439-1445.
59. Kanwar YS, Wada J, Sun L, Xie P, Wallner EI, Chen S, Chugh S, Danesh FR: Diabetic nephropathy: Mechanisms of renal disease progression. Exp Biol Med (Maywood) (2008) 233(1):4-11.
60. Xia L, Wang H, Munk S, Frecker H, Goldberg HJ, Fantus IG, Whiteside CI: Reactive oxygen species, PKC-β1, and PKC-γ1 mediate high-glucose-induced vascular endothelial growth factor expression in mesangial cells. Am J Physiol Endocrinol Metab (2007) 293(5):E1280-1288.
61. Feliers D, Gorin Y, Ghosh-Choudhury G, Abboud HE, Kasinath BS: Angiotensin II stimulation of VEGF mRNA translation requires production of reactive oxygen species. Am J Physiol Renal Physiol (2006) 290(4):F927-F936.
62. Tilton RG: Diabetic vascular dysfunction: Links to glucoseinduced reductive stress and VEGF. Microsc Res Tech (2002) 57(5):390-407.
63. Berthier CC, Zhang H, Schin M, Henger A, Nelson RG, Yee B, Boucherot A, Neusser MA, Cohen CD, Carter-Su C, Argetsinger LS et al: Enhanced expression of Janus kinase-signal transducer and activator of transcription pathway members in human diabetic nephropathy. Diabetes (2009) 58(2):469-477.
64. Marrero MB, Banes-Berceli AK, Stern DM, Eaton DC: Role of the JAK/STAT signaling pathway in diabetic nephropathy. Am J Physiol Renal Physiol (2006) 290(4):F762-F768.
65. Drel VR, Pacher P, Stevens MJ, Obrosova IG: Aldose reductase inhibition counteracts nitrosative stress and poly(ADP-ribose) polymerase activation in diabetic rat kidney and high-glucoseexposed human mesangial cells. Free Radic Biol Med (2006) 40(8):1454-1465.
66. Forbes JM, Coughlan MT, Cooper ME: Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes (2008) 57(6):1446-1454.
67. Pacher P, Beckman JS, Liaudet L: Nitric oxide and peroxynitrite in health and disease. Physiol Rev (2007) 87(1):315-424.
68. Schrijvers BF, De Vriese AS: Novel insights in the treatment of diabetic nephropathy. Acta Clin Belg (2007) 62(5):278-290.
69. Rosolowsky ET, Ficociello LH, Maselli NJ, Niewczas MA, Binns AL, Roshan B, Warram JH, Krolewski AS: High-normal serum uric acid is associated with impaired glomerular filtration rate in nonproteinuric patients with type 1 diabetes. Clin J Am Soc Nephrol (2008) 3(3):706-713.
70. Hovind P, Rossing P, Tarnow L, Johnson RJ, Parving HH: Serum uric acid as a predictor for development of diabetic nephropathy in type 1 diabetes: An inception cohort study. Diabetes (2009) 58(7):1668-1671.
71. Forbes JM, Fukami K, Cooper ME: Diabetic nephropathy: Where hemodynamics meets metabolism. Exp Clin Endocrinol Diabetes (2007) 115(2):69-84.
72. Gnudi L, Thomas SM, Viberti G: Mechanical forces in diabetic kidney disease: A trigger for impaired glucose metabolism. J Am Soc Nephrol (2007) 18(8):2226-2232.
73. Mauer M, Zinman B, Gardiner R, Suissa S, Sinaiko A, Strand T, Drummond K, Donnelly S, Goodyer P, Gubler MC, Klein R: Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med (2009) 361(1):40-51.
74. Bilous R, Chaturvedi N, Sjølie AK, Fuller J, Klein R, Orchard T, Porta M, Parving HH: Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: Three randomized trials. Ann Intern Med (2009) 151(1):11-20.
75. Jerums G, Panagiotopoulos S, Premaratne E, Power DA, MacIsaac RJ: Lowering of proteinuria in response to antihypertensive therapy predicts improved renal function in late but not in early diabetic nephropathy: A pooled analysis. Am J Nephrol (2008) 28(4):614-627.
76. Griffin KA, Bidani AK: Progression of renal disease: Renoprotective specificity of renin-angiotensin system blockade. Clin J Am Soc Nephrol (2006) 1(5):1054-1065.
77. Casas JP, Chua W, Loukogeorgakis S, Vallance P, Smeeth L, Hingorani AD, MacAllister RJ: Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: Systematic review and meta-analysis. Lancet (2005) 366(9502):2026-2033.
78. Penning TM, Drury JE: Human aldo-keto reductases: Function, gene regulation, and single nucleotide polymorphisms. Arch Biochem Biophys (2007) 464(2):241-250.
79. Dagher Z, Park YS, Asnaghi V, Hoehn T, Gerhardinger C, Lorenzi M: Studies of rat and human retinas predict a role for the polyol pathway in human diabetic retinopathy. Diabetes (2004) 53(9):2404-2411.
80. Sands JM, Terada Y, Bernard LM, Knepper MA: Aldose reductase activities in microdissected rat renal tubule segments. Am J Physiol (1989) 256(4 Pt 2):F563-F569.
81. Corder CN, Braughler JM, Culp PA: Quantitative histochemistry of the sorbitol pathway in glomeruli and small arteries of human diabetic kidney. Folia Histochem Cytochem (Krakow) (1979) 17(2):137-145.
82. Kasajima H, Yamagishi S-I, Sugai S, Yagihashi N, Yagihashi S: Enhanced in situ expression of aldose reductase in peripheral nerve and renal glomeruli in diabetic patients. Virchows Arch (2001) 439(1):46-54.
83. Burg MB, Ferraris JD: Intracellular organic osmolytes: Function and regulation. J Biol Chem (2008) 283(12):7309-7313.
84. Yang JY, Tam WY, Tam S, Guo H, Wu X, Li G, Chau JF, Klein JD, Chung SK, Sands JM, Chung SS: Genetic restoration of aldose reductase to the collecting tubules restores maturation of the urine concentrating mechanism. Am J Physiol Renal Physiol (2006) 291(1):F186-F195.
85. Ho EC, Lam KS, Chen YS, Yip JC, Arvindakshan M, Yamagishi S, Yagihashi S, Oates PJ, Ellery CA, Chung SS, Chung SK: Aldose reductase-deficient mice are protected from delayed motor nerve conduction velocity, increased c-Jun NH2- terminal kinase activation, depletion of reduced glutathione, increased superoxide accumulation, and DNA damage. Diabetes (2006) 55(7):1946-1953.
86. Cheung AK, Fung MK, Lo AC, Lam TT, So KF, Chung SS, Chung SK: Aldose reductase deficiency prevents diabetes-induced blood-retinal barrier breakdown, apoptosis, and glial reactivation in the retina of db/db mice. Diabetes (2005) 54(11):3119-3125.
87. Yamaoka T, Nishimura C, Yamashita K, Itakura M, Yamada T, Fujimoto J, Kokai Y: Acute onset of diabetic pathological changes in transgenic mice with human aldose reductase cDNA. Diabetologia (1995) 38(3):255-261.
88. Grimshaw CE: Aldose reductase: Model for a new paradigm of enzymic perfection in detoxification catalysts. Biochemistry (1992) 31(42):10139-10145.
89. Srivastava S, Liu SQ, Conklin DJ, Zacarias A, Srivastava SK, Bhatnagar A: Involvement of aldose reductase in the metabolism of atherogenic aldehydes. Chem Biol Interact (2001) 130-132(1-3):563-571.
90. Srivastava S, Vladykovskaya E, Barski OA, Spite M, Kaiserova K, Petrash JM, Chung SS, Hunt G, Dawn B, Bhatnagar A: Aldose reductase protects against early atherosclerotic lesion formation in apolipoprotein E-null mice. Circ Res (2009) 105(8):793-802.
91. Obrosova IG: Increased sorbitol pathway activity generates oxidative stress in tissue sites for diabetic complications. Antioxid Redox Signal (2005) 7(11-12):1543-1552.
92. Chung SS, Chung SK: Aldose reductase in diabetic microvascular complications. Curr Drug Targets (2005) 6(4): 475-486.
93. Vikramadithyan RK, Hu Y, Noh HL, Liang CP, Hallam K, Tall AR, Ramasamy R, Goldberg IJ: Human aldose reductase expression accelerates diabetic atherosclerosis in transgenic mice. J Clin Invest (2005) 115(9):2434-2443.
94. Gleissner CA, Sanders JM, Nadler J, Ley K: Upregulation of aldose reductase during foam cell formation as possible link among diabetes, hyperlipidemia, and atherosclerosis. Arterioscler Thromb Vasc Biol (2008) 28(6):1137-1143.
95. Hwang YC, Kaneko M, Bakr S, Liao H, Lu Y, Lewis ER, Yan S, II S, Itakura M, Rui L, Skopicki H et al: Central role for aldose reductase pathway in myocardial ischemic injury. FASEB J (2004) 18(11):1192-1199.
96. Lo ACY, Cheung AKH, Hung VKL, Yeung CM, He QY, Chiu JF, Chung SSM, Chung SK: Deletion of aldose reductase leads to protection against cerebral ischemic injury. J Cereb Blood Flow Metab (2007) 27(8):1496-1509.
97. Reddy AB, Ramana KV: Aldose reductase inhibition: Emerging drug target for the treatment of cardiovascular complications. Recent Pat Cardiovasc Drug Discov (2010) 5(1): 25-32.
98. Huang P, Zhang Y, Jiang T, Zeng W, Zhang N: Aldose reductase is a potent regulator of TGF-β1 induced expression of fibronectin in human mesangial cells. Mol Biol Rep (2009):doi:10.1007/s11033-009-9887-6.
99. Alexiou P, Pegklidou K, Chatzopoulou M, Nicolaou I, Demopoulos VJ: Aldose reductase enzyme and its implication to major health problems of the 21st century. Curr Med Chem (2009) 16(6): 734-752.
100. Chalk C, Benstead TJ, Moore F: Aldose reductase inhibitors for the treatment of diabetic polyneuropathy. Cochrane Database Syst Rev (2007) 17(4):CD004572.
101. Gabbay KH: The sorbitol pathway and the complications of diabetes. N Engl J Med (1973) 288(16):831-836.
102. Kador PF, Robison WG Jr, Kinoshita JH: The pharmacology of aldose reductase inhibitors. Annu Rev Pharmacol Toxicol (1985) 25:691-714.
103. Lee AY, Chung SK, Chung SS: Demonstration that polyol accumulation is responsible for diabetic cataract by the use of transgenic mice expressing the aldose reductase gene in the lens. Proc Natl Acad Sci USA (1995) 92(7):2780-2784.
104. Daniels BS, Hostetter TH: Aldose reductase inhibition and glomerular abnormalities in diabetic rats. Diabetes (1989) 38(8):981-986.
105. Soulis-Liparota T, Cooper ME, Dunlop M, Jerums G: The relative roles of advanced glycation, oxidation and aldose reductase inhibition in the development of experimental diabetic nephropathy in the Sprague-Dawley rat. Diabetologia (1995) 38(4):387-394.
106. Pacher P, Szabó C: Role of peroxynitrite in the pathogenesis of cardiovascular complications of diabetes. Curr Opin Pharmacol (2006) 6(2):136-141.
107. Eggler JF, Larson ER, Lipinski CA, Mylari BL, Urban FJ: A perspective of aldose reductase inhibitors. In: Advances in Medicinal Chemistry: Volume 2. Maryanoff BE, Maryanoff CA (Eds), JAI Press, Greenwich, CT, USA (1993):197-246.
108. Bril V, Hirose T, Tomioka S, Buchanan R, Ranirestat Study G: Ranirestat for the management of diabetic sensorimotor polyneuropathy. Diabetes Care (2009) 32(7):1256-1260.
109. Barski OA, Gabbay KH, Grimshaw CE, Bohren KM: Mechanism of human aldehyde reductase: Characterization of the active site pocket. Biochemistry (1995) 34(35):11264-11275.
110. Hostetter TH, Olson JL, Rennke HG, Venkatachalam MA, Brenner BM: Hyperfiltration in remnant nephrons: A potentially adverse response to renal ablation. Am J Physiol (1981) 241(1):F85-F93.
111. Ficociello LH, Perkins BA, Roshan B, Weinberg JM, Aschengrau A, Warram JH, Krolewski AS: Renal hyperfiltration and the development of microalbuminuria in type 1 diabetes. Diabetes Care (2009) 32(5):889-893.
112. Magee GM, Bilous RW, Cardwell CR, Hunter SJ, Kee F, Fogarty DG: Is hyperfiltration associated with the future risk of developing diabetic nephropathy? A meta-analysis. Diabetologia (2009) 52(4):691-697.
113. Bank N, Mower P, Aynedjian HS, Wilkes BM, Silverman S: Sorbinil prevents glomerular hyperperfusion in diabetic rats. Am J Physiol (1989) 256(6 Pt 2):F1000-1006.
114. Tilton RG, Chang K, Pugliese G, Eades DM, Province MA, Sherman WR, Kilo C, Williamson JR: Prevention of hemodynamic and vascular albumin filtration changes in diabetic rats by aldose reductase inhibitors. Diabetes (1989) 37(10):1258-1270.
115. Haraldsson B, Nyström J, Deen WM: Properties of the glomerular barrier and mechanisms of proteinuria. Physiol Rev (2008) 88(2):451-487.
116. Beyer-Mears A, Cruz E, Edelist T, Varagiannis E: Diminished proteinuria in diabetes mellitus by sorbinil, an aldose reductase inhibitor. Pharmacology (1986) 32(1):52-60.
117. McCaleb ML, Sredy J, Millen J, Ackerman DM, Dvornik D: Prevention of urinary albumin excretion in 6 month streptozocin-diabetic rats with the aldose reductase inhibitor tolrestat. J Diabetic Complications (1988) 2(1):16-18.
118. Goldfarb S, Ziyadeh FN, Kern EF, Simmons DA: Effects of polyol-pathway inhibition and dietary myo-inositol on glomerular hemodynamic function in experimental diabetes mellitus in rats. Diabetes (1991) 40(4):465-471.
119. Pedersen MM, Christiansen JS, Mogensen CE: Reduction of glomerular hyperfiltration in normoalbuminuric IDDM patients by 6 mo of aldose reductase inhibition. Diabetes (1991) 40(5):527-531.
120. Passariello N, Sepe J, Marrazzo G, De Cicco A, Castellano L, Peluso A, Pisano MCA, Sgambato S, Tesauro P, D'Onofrio F: Effect of aldose reductase inhibitor (tolrestat) on urinary albumin excretion rate and glomerular filtration rate in IDDM subjects with nephropathy. Diabetes Care (1993) 16(5):789-795.
121. Pedersen MM, Mogensen CE, Christiansen JS: Reduction of glomerular hyperfiltration during short-term aldose reductase inhibition in normoalbuminuric, insulin-dependent diabetic patients. Endocrinol Metab (1995) 2:55-62.
122. Blohmé G, Smith U: Aldose reductase inhibition reduces urinary albumin excretion rate in incipient diabetic nephropathy. Diabetologia (1989) 32:Abs 467A.
123. Oates PJ, Klioze SS, Schwartz PF, Boland AD, The Zopolrestat Diabetic Nephropathy Study Group: Aldose reductase inhibitor zopolrestat reduces elevated urinary albumin excretion rate in type 1 diabetes mellitus subjects with incipient diabetic nephropathy. J Am Soc Nephrol (2008) 19:Abs 642A.
124. Iso K, Tada H, Kuboki K, Inokuchi T: Long-term effect of epalrestat, an aldose reductase inhibitor, on the development of incipient diabetic nephropathy in type 2 diabetic patients. J Diabetes Complications (2001) 15(5):241-244.
125. Ido Y, Nyengaard JR, Chang K, Tilton RG, Kilo C, Mylari BL, Oates PJ, Williamson JR: Early neural and vascular dysfunction in diabetic rats are largely sequelae of increased sorbitol oxidation. Antioxid Redox Signal (2010) 12(1):39-51.
126. Tilton RG, Baier LD, Harlow JE, Smith SR, Ostrow E, Williamson JR: Diabetes-induced glomerular dysfunction: Links to a more reduced cytosolic ratio of NADH/NAD+. Kidney Int (1992) 41(4):778-788.
127. Brown LF, Berse B, Tognazzi K, Manseau EJ, Van de Water L, Senger DR, Dvorak HF, Rosen S: Vascular permeability factor mRNA and protein expression in human kidney. Kidney Int (1992) 42(6):1457-1461.
128. Ludvigson MA, Sorenson RL: Immunohistochemical localization of aldose reductase. II. Rat eye and kidney. Diabetes (1980) 29(6):450-459.
129. Ziyadeh FN, Wolf G: Pathogenesis of the podocytopathy and proteinuria in diabetic glomerulopathy. Curr Diabetes Rev (2008) 4(1):39-45.
130. Ku CH, White KE, Dei Cas A, Hayward A, Webster Z, Bilous R, Marshall S, Viberti G, Gnudi L: Inducible overexpression of sFlt-1 in podocytes ameliorates glomerulopathy in diabetic mice. Diabetes (2008) 57(10):2824-2833.
131. Oates P, Ellery CA: Vascular endothelial growth factor immunoreactivity is reduced in serum and plasma from diabetic rats treated with an aldose reductase inhibitor. Diabetes (2000) 49(Suppl 1):Abs A377.
132. Tilton RG, Kawamura T, Chang KC, Ido Y, Bjercke RJ, Stephan CC, Brock TA, Williamson JR: Vascular dysfunction induced by elevated glucose levels in rats is mediated by vascular endothelial growth factor. J Clin Invest (1997) 99(9):2192-2202.
133. Mauer SM, Steffes MW, Azar S, Brown DM: Effects of sorbinil on glomerular structure and function in long-term-diabetic rats. Diabetes (1989) 38(7):839-846.
134. Itagaki I, Shimizu K, Kamanaka Y, Ebata K, Kikkawa R, Haneda M, Shigeta Y: The effect of an aldose reductase inhibitor (epalrestat) on diabetic nephropathy in rats. Diabetes Res Clin Pract (1994) 25(3):147-154.
135. Sanchez AP, Sharma K: Transcription factors in the pathogenesis of diabetic nephropathy. Expert Rev Mol Med (2009) 11:e13.
136. Yang B, Hodgkinson AD, Oates PJ, Kwon HM, Millward BA, Demaine AG: Elevated activity of transcription factor nuclear factor of activated T-cells 5 (NFAT5) and diabetic nephropathy. Diabetes (2006) 55(5):1450-1455.
137. Yang B, Hodgkinson A, Oates PJ, Millward BA, Demaine AG: High glucose induction of DNA-binding activity of the transcription factor NFκB in patients with diabetic nephropathy. Biochim Biophys Acta (2008) 1782(5):295-302.
138. Sharma K, Ziyadeh FN: Hyperglycemia and diabetic kidney disease. The case for transforming growth factor-β as a key mediator. Diabetes (1995) 44(10):1139-1146.
139. Sharma K, Ziyadeh FN, Alzahabi B, McGowan TA, Kapoor S, Kurnik BR, Kurnik PB, Weisberg LS: Increased renal production of transforming growth factor-β1 in patients with type II diabetes. Diabetes (1997) 46(5):854-859.
140. Ishii H, Tada H, Isogai S: An aldose reductase inhibitor prevents glucose-induced increase in transforming growth factor-β and protein kinase C activity in cultured human mesangial cells. Diabetologia (1998) 41(4):362-364.
141. Dan Q, Wong RLC, Yin S, Chung SK, Chung SSM, Lam KSL: Interaction between the polyol pathway and non-enzymatic glycation on mesangial cell gene expression. Nephron (2004) 98(3):e89-e99.
142. Hamada Y, Nakamura J, Naruse K, Komori T, Kato K, Kasuya Y, Nagai R, Horiuchi S, Hotta N: Epalrestat, an aldose reductase ihibitor, reduces the levels of Nε-(carboxymethyl)lysine protein adducts and their precursors in erythrocytes from diabetic patients. Diabetes Care (2000) 23(10):1539-1544.
143. Jono T, Nagai R, Lin X, Ahmed N, Thornalley PJ, Takeya M, Horiuchi S: Nε-(carboxymethyl)lysine and 3-DG-imidazolone are major AGE structures in protein modification by 3-deoxyglucosone. J Biochem (2004) 136(3):351-358.
144. Niwa T, Tsukushi S: 3-Deoxyglucosone and AGEs in uremic complications: Inactivation of glutathione peroxidase by 3-deoxyglucosone. Kidney Int Suppl (2001) 78:S37-S41.
145. Miyata T, Sugiyama S, Suzuki D, Inagi R, Kurokawa K: Increased carbonyl modification by lipids and carbohydrates in diabetic nephropathy. Kidney Int Suppl (1999) 71:S54-S56.
146. Berrou J, Tostivint I, Verrecchia F, Berthier C, Boulanger E, Mauviel A, Marti HP, Wautier MP, Wautier JL, Rondeau E, Hertig A: Advanced glycation end products regulate extracellular matrix protein and protease expression by human glomerular mesangial cells. Int J Mol Med (2009) 23(4):513-520.
147. Demaine AG: Polymorphisms of the aldose reductase gene and susceptibility to diabetic microvascular complications. Curr Med Chem (2003) 10(15):1389-1398.
148. Xu M, Chen X, Yan L, Cheng H, Chen W: Association between (AC)n dinucleotide repeat polymorphism at the 5'- end of the aldose reductase gene and diabetic nephropathy: A meta-analysis. J Mol Endocrinol (2008) 40(5):243-251.
149. Rogus JJ, Warram JH, Krolewski AS: Genetic studies of late diabetic complications: The overlooked importance of diabetes duration before complication onset. Diabetes (2002) 51(6):1655-1662.
150. Shah VO, Scavini M, Nikolic J, Sun Y, Vai S, Griffith JK, Dorin RI, Stidley C, Yacoub M, Vander Jagt DL, Eaton RP et al: Z-2 microsatellite allele is linked to increased expression of the aldose reductase gene in diabetic nephropathy. J Clin Endocrinol Metab (1998) 83(8):2886-2891.
151. Hodgkinson AD, Søndergaard KL, Yang B, Cross DF, Millward BA, Demaine AG: Aldose reductase expression is induced by hyperglycemia in diabetic nephropathy. Kidney Int (2001) 60(1):211-218.
152. Oates PJ, Mylari BL: Aldose reductase inhibitors: Therapeutic implications for diabetic complications. Expert Opin Investig Drugs (1999) 8(12):2095-2119.
153. Zhao HL, Tong PC, Lai FM, Tomlinson B, Chan JC: Association of glomerulopathy with the 5'-end polymorphism of the aldose reductase gene and renal insufficiency in type 2 diabetic patients. Diabetes (2004) 53(11):2984-2991.
154. So WY, Wang Y, Ng MC, Yang X, Ma RC, Lam V, Kong AP, Tong PC, Chan JC: Aldose reductase genotypes and cardiorenal complications: An 8-year prospective analysis of 1,074 type 2 diabetic patients. Diabetes Care (2008) 31(11):2148-2153.
155. Hodgkinson AD, Bartlett T, Oates PJ, Millward BA, Demaine AG: The response of antioxidant genes to hyperglycemia is abnormal in patients with type 1 diabetes and diabetic nephropathy. Diabetes (2003) 52(3):846-851.
156. Ceriello A, Morocutti A, Mercuri F, Quagliaro L, Moro M, Damante G, Viberti GC: Defective intracellular antioxidant enzyme production in type 1 diabetic patients with nephropathy. Diabetes (2000) 49(12):2170-2177.
157. Obrosova IG, Minchenko AG, Vasupuram R, White L, Abatan OI, Kumagai AK, Frank RN, Stevens MJ: Aldose reductase inhibitor fidarestat prevents retinal oxidative stress and vascular endothelial growth factor overexpression in streptozotocindiabetic rats. Diabetes (2003) 52(3):864-871.
158. +-ATPase activity. Am J Physiol (2002) 282(3):C560-566.
159. Stevens MJ, Obrosova IG, Cao X, Van Huysen C, Greene DA: Effects of dl-α-lipoic acid on peripheral nerve conduction, blood flow, energy metabolism, and oxidative stress in experimental diabetic neuropathy. Diabetes (2000) 49(6):1006-1015.
160. Granier C, Makni K, Molina L, Jardin-Watelet B, Ayadi H, Jarraya F: Gene and protein markers of diabetic nephropathy. Nephrol Dial Transplant (2008) 23(3):792-799.
161. Hodgkinson AD, Millward BA, Demaine AG: Polymorphisms of the glucose transporter (GLUT1) gene are associated with diabetic nephropathy. Kidney Int (2001) 59(3):985-989.
162. Al-Kateb H, Boright AP, Mirea L, Xie X, Sutradhar R, Mowjoodi A, Bharaj B, Liu M, Bucksa JM, Arends VL, Steffes MW et al: Multiple superoxide dismutase 1/splicing factor serine alanine 15 variants are associated with the development and progression of diabetic nephropathy: The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Genetics Study. Diabetes (2008) 57(1): 218-228.
163. Pezzolesi MG, Poznik GD, Mychaleckyj JC, Paterson AD, Barati MT, Klein JB, Ng DP, Placha G, Canani LH, Bochenski J, Waggott D et al: Genome-wide association scan for diabetic nephropathy susceptibility genes in type 1 diabetes. Diabetes (2009) 58(6):1403-1410.
164. MG, Katavetin P, Kure M, Poznik GD, Skupien J, Mychaleckyj JC, Rich SS, Warram JH, Krolewski AS: Confirmation of genetic associations at ELMO1 in the GoKinD collection supports its role as a susceptibility gene in diabetic nephropathy. Diabetes (2009) 58(11):2698-2702.
165. Möllsten A, Jorsal A, Lajer M, Vionnet N, Tarnow L: The V16A polymorphism in SOD2 is associated with increased risk of diabetic nephropathy and cardiovascular disease in type 1 diabetes. Diabetologia (2009) 52(12):2590-2593.
166. Oates P, Ellery C, Beebe D, Coutcher J, Qian Y-Z, Phillips D, Lowe V, Appleton T, Raunig D, O'Neill S, Mylari BL: Sorbitol dehydrogenase inhibition as well as aldose reductase inhibition prevents elevation of urinary albumin excretion in diabetic rats. Diabetologia (2004) 47(Suppl 1):Abs 398.
167. Oates P, Ellery C, Beebe D, Coutcher J, Qian Y-Z, Lowe V, O'Neill S: Reduction of elevated urinary albumin excretion in diabetic rats by polyol pathway inhibitors correlates with changes in urinary sorbitol excretion. Diabetes (2005) 54(Suppl 1):Abs 195.
168. Fioretto P, Steffes MW, Sutherland DE, Goetz FC, Mauer M: Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med (1998) 339(2):69-75.